Millendo Therapeutics Stock

MLND

US60040X1037

Biotechnology & Medical Research

Latest news : Millendo Therapeutics

23-05-10	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
22-12-29	Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	CI
21-09-30	Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer	CI
21-06-25	Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index	CI
21-06-24	Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	CI
21-06-22	Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	MT
21-05-13	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
21-03-29	Millendo Therapeutics, Inc., Tempest Therapeutics Inc. - M&A Call
21-03-29	Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ	MT
21-03-29	Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
21-03-28	Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction.	CI
21-01-28	Millendo Therapeutics, Inc. Announces Executive Changes	CI
21-01-28	Millendo Therapeutics, Inc. Plans to Reduce Its Workforce with Majority of Reduction in Personnel Expects to Complete by April 15, 2021	CI

More news

Analysts' recommendations: Millendo Therapeutics

21-01-06	MILLENDO THERAPEUTICS : Ladenburg Thalmann Downgrades Millendo Therapeutics to Neutral from Buy	MT
21-01-06	MILLENDO THERAPEUTICS : SVB Leerink Downgrades Millendo Therapeutics to Market Perform From Outperform; Price Target is $2	MT
20-11-09	MILLENDO THERAPEUTICS : Wedbush Adjusts Price Target for Millendo Therapeutics to $2 From $3, Maintains Neutral Rating	MT

More recommendations

Press Releases: Millendo Therapeutics

21-07-23	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
21-07-16	Tempest Therapeutics : BUSINESS (Form 8-K)	PU
21-07-16	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
21-07-12	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	AQ
21-07-12	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MILLENDO THERAPEUTICS	-14.88%	+3.21%	-	-	303M
LONZA GROUP AG	-0.41%	+7.24%	-5.04%	+2.49%	46.36B
REVOLUTION MEDICINES, INC.	+1.08%	+8.83%	+381.44%	+625.55%	37.88B
IQVIA HOLDINGS INC.	+1.02%	+12.88%	+19.77%	-11.41%	31.12B
BEONE MEDICINES AG	-0.44%	+1.21%	+8.09%	+52.75%	30.61B
CELLTRION, INC.	+0.23%	-0.29%	+13.24%	+21.10%	24.69B
ASCENDIS PHARMA A/S	-0.03%	+15.62%	-	-	16.25B
MEDPACE HOLDINGS, INC.	+0.20%	+14.00%	+69.32%	+130.76%	14.85B
EUROFINS SCIENTIFIC SE	+0.38%	+9.63%	+12.62%	+22.09%	13.58B
IONIS PHARMACEUTICALS, INC.	+4.91%	+5.51%	+101.28%	+104.78%	12.95B
Average	-0.83%	+8.21%	+75.09%	+118.51%	25.36B
Weighted average by Cap.	+0.48%	+8.01%	+84.50%	+137.66%

See all sector performances

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Employees

Sector

Biotechnology & Medical Research

More about the company